Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.
<h4>Objective</h4>The aim of this study was to assess the seroconversion rate and percent inhibition of neutralizing antibodies against the wild-type and Omicron variants of SARS-CoV-2 in patients with solid cancer who received two COVID-19 vaccine doses by comparing chemotherapy and non...
Saved in:
| Main Authors: | Busyamas Chewaskulyong, Pattarapong Satjaritanun, Thanika Ketpueak, Thatthan Suksombooncharoen, Chaiyut Charoentum, Nuttaphoom Nuchpong, Apichat Tantraworasin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0310781 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of PM2.5 exposure on mortality and tumor recurrence in resectable non-small cell lung carcinoma
by: Bongkotmas Kosanpipat, et al.
Published: (2024-10-01) -
Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
by: Hongjie Xia, et al.
Published: (2023-12-01) -
Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies
by: Lei You, et al.
Published: (2025-05-01) -
SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization.
by: Enya Qing, et al.
Published: (2024-12-01) -
Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)